Tom Frohlich's most recent trade in Jade Biosciences Inc was a trade of 472,500 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 12, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Jade Biosciences Inc | Tom Frohlich | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 472,500 | 472,500 | - | - | Stock Option (Right to Buy) | |
| Jade Biosciences Inc | Tom Frohlich | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 78,750 | 86,331 | - | 0 | Common Stock | |
| Jade Biosciences Inc | Tom Frohlich | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 7.40 per share. | 16 May 2025 | 6,000 | 6,000 | - | 7.4 | 44,400 | Common Stock |